Daiichi Sankyo Company, Limited · TSE:4568

Daiichi Sankyo — Investor Presentation (May 2005)

33 slides from Daiichi Sankyo's investor presentation, May 13, 2005

1. Slide 1: Cather QS

   Cather QS SANKYO pancHt

2. Slide 2: SANKYO

   © =exex os 1 SANKYO

3. Slide 3: CG =texex Po) SEEKS

   CG =texex Po) SEEKS SANKYO oancn

4. Slide 4: Daiichi Sankyo Company, Limited

   1-1 DAIICHI SANKYO COMPANY, LIMITED 3 5 1 2005 9 21 2005 9 28 2005 9 28 1 1 1.159 1 3

5. Slide 5: Global Pharma Innovator

   1-2 Global Pharma Innovator 4

6. Slide 6: CAGR* 3 CAGR* 3

   1-3 2009 2,500 : 2004 2007 2009 7,580 7,620 9,320 CAGR*3 4% 4,470 4,610 5,040 2,560 2,530 3,760 300 360 360 *2 250 120 160 + 6,310 6,050 6,770 1,400 1,650 1,700 1,270 1,570 2,550 CAGR*3 16.8% 20.6% 27.4% 15% 4 390 560 5.1% 6.0% *1 2007 2009 2004 *2 *3 2004 -2009 *4 5

7. Slide 7: Global Pharma Innovator

   1-4 Global Pharma Innovator Global Pharma Innovator * 2005 2 18 * 6

8. Slide 8: 1-5 z z

   1-5 z z 7

9. Slide 9: & =sesxtatt palm asine)

   & =sesxtatt palm asine) 8 SANKYO teen

10. Slide 10: CG =texex Po) SEEKS

    CG =texex Po) SEEKS SANKYO oancn

11. Slide 11: 2-1 2007 2007 2009 2009 *3 *2 *2 * 930 670 *1 560 1

    2-1 2007 2007 2009 2009 *3 *2 190 360 *2 * 3 180 170 160 120 930 670 *1 560 1 * 570 500 390 *1 *2 = *3 10

12. Slide 12: 2-2 2007 2009 „ „ „ „ IT „ „ „ „ „ 570

    2-2 2007 2009 230 290 „ „ „ „ IT 220 230 „ „ „ 50 50 „ „ 500 570 „ 11

13. Slide 13: 2-3 2009 15,000 40% 15,500 15,000 14,600 2,900 19% 4,800 3,300 3,300 31% 23%

    2-3 2009 15,000 40% 15,500 15,000 14,600 2,900 19% 4,800 3,300 3,300 31% 23% 22% 6,300 1,900 5,700 12% 39% 42% 2,400 3,000 16% 20% 10,700 69% 8,900 8,700 61% 58% 2004 2007 2009 * 12

14. Slide 14: 2-4.1 ** 2007 2009 2007 2009 * =

    2-4.1 ** 2007 2009 2007 2009 * = 13

15. Slide 15: *2 IMS JDI 2004

    2-4.2 2005 10 *1 z 2,500 MR 1 *2 *1 *2 IMS JDI 2004 14

16. Slide 16: z 2005 z ARB*

    E E e@2005 10 e ARB* e © =texexn PoyRcBeetat 15

17. Slide 17: ARB

    2-4.4 1 ARB*1 ARB* 3 *2 2009 1,000 3 *1 *2 16

18. Slide 18: G=xuxex PE Seeest

    E 15 E 2007 3 | 1,700 90 G=xuxex PE Seeest 17

19. Slide 19: C=tetear B= SSesst

    | 1,180 | 90% 2006 * C=tetear B= SSesst 18 SANKYO

20. Slide 20: CG =texex Po) SEEKS

    CG =texex Po) SEEKS SANKYO oancn 19

21. Slide 21: SG =sexex Pj) BERR

    4 SG =sexex Pj) BERR 20 SANKYO teen

22. Slide 22: CS-747 DU-176b CS-505

    3-2.1 CS-747 DU-176b CS-505 „ CS-3030 „SUN N8075 „ DU-176b „ CS-505 „ CS-747 „ DZ-697b „ SUN N4057 „ HGF „ DX-9065a „ CS-011 „ SNK-860 „ WelChol „ CS-917 diabetes „ D-100 „ DX-619 „ DU-6859a „ CS-8958 „ CS-758 „ CS-1008 „ DJ-927 „ CS-7017 „ CS-0777 „ DW-908e „ CS-003 „ CS-706 * 21

23. Slide 23: Pipeline by therapeutic area

    3-2.2 Anti-platelet CS-747 DZ-697b* Anti-arteriosclerosis Anti-FXa CS-505 DU-176b CS-3030* Anti-diabetes WelChol diabetes CS-011 CS-917 SNK-860 Anti-hyperlipidemia WelChol® Anti-hypertension Benicar® Advanced Therapy Benicar HCT® HGF plasmid * 22

24. Slide 24: New R&D decision structure

    3-3 2005 9 2005 10 John C. Alexander* Global R&D New R&D Management 2005 Decision Committee 10 Committee Integrated Scientific Board Development Team /Core Team * SPhD Sankyo Pharma Development Division President GRDMC 23

25. Slide 25: NPV

    3-4 NPV NPV * CS-747 * -3 -2 -1 0 1 2 3 4 5 6 * 24

26. Slide 26: G stexer QS

    G stexer QS 25 SANKYO

27. Slide 27: CG =texex Po) SEEKS

    CG =texex Po) SEEKS SANKYO oancn 26

28. Slide 28: CEO

    | : CEO nnn ” CEO G=xeten GRessan er

29. Slide 29: CEO

    CEO G =xnxan pMeesee 28 SANKYO

30. Slide 30: CEO

    4-3 CEO CEO 29

31. Slide 31: Integrate and Go / Virtual Integration

    4-4 “Integrate and Go” “Virtual Integration” 2005 10 R&D “Integrate and Go” “Go and Integrate” „ „ „ „ 2007 2009 „ * 170 360 „ „ * 500 570 „ * = 30

32. Slide 32: 4-5 2005 „ „ 2006 „ „ „ 2007 „ 2007 „

    4-5 2005 10 „ „ 2006 4 „ „ „ 2007 3 „ 2007 4 „ 31

33. Slide 33: Global Pharma Innovator

    G=xexexn Pecweetat 32 SANKYO

Daiichi Sankyo Company — Investor Presentation (May 2005) on 6ix